Company Summary

CytoDel is a biopharmaceutical company that uses the tools of 21st century molecular biology to produce recombinant derivatives of botulinum neurotoxin (BoNT) customized to specific applications. The technology allows CytoDel to manipulate the BoNT molecule, for next generation BoNT products and into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons.

Year Founded:  2012

Key Executives:
• Phillip Band, CEO
• Konstantin Ichtchenko, CSO

Location:  New York, NY


Company Status:  Private

Year Invested:  2018

Investment Status:  Current

Board Member:
Todd Thomson (Observer)